Hologic (NASDAQ:HOLX) had its price target upped by Needham & Company LLC from $64.00 to $78.00 in a research note released on Thursday, The Fly reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.
A number of other research firms have also recently commented on HOLX. William Blair reiterated an outperform rating on shares of Hologic in a report on Monday, July 27th. TheStreet upgraded shares of Hologic from a c+ rating to a b- rating in a research report on Thursday, May 14th. SVB Leerink increased their price objective on shares of Hologic from $62.00 to $66.00 and gave the company an outperform rating in a research report on Wednesday, July 15th. BTIG Research restated a buy rating and set a $84.00 price objective (up previously from $63.00) on shares of Hologic in a research report on Wednesday. Finally, Zacks Investment Research downgraded shares of Hologic from a hold rating to a sell rating and set a $52.00 price objective on the stock. in a research report on Tuesday, April 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $65.38.
HOLX stock traded up $0.07 during trading on Thursday, reaching $69.78. The company had a trading volume of 2,584,378 shares, compared to its average volume of 1,982,671. Hologic has a 52 week low of $26.49 and a 52 week high of $70.35. The company has a market cap of $18.07 billion, a P/E ratio of 28.25, a PEG ratio of 3.69 and a beta of 1.47. The business has a 50 day moving average of $57.42 and a 200 day moving average of $50.06. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.47 and a quick ratio of 1.04.
In other news, CEO Stephen P. Macmillan sold 190,996 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total transaction of $9,735,066.12. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Peter J. Valenti III sold 10,493 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $51.82, for a total transaction of $543,747.26. The disclosure for this sale can be found here. Insiders have sold a total of 243,932 shares of company stock worth $12,507,250 over the last 90 days. Insiders own 1.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in HOLX. Norges Bank bought a new stake in shares of Hologic during the 4th quarter valued at $153,506,000. Teacher Retirement System of Texas purchased a new position in shares of Hologic during the 1st quarter worth about $34,864,000. Frontier Capital Management Co. LLC purchased a new position in shares of Hologic during the 2nd quarter worth about $44,943,000. AQR Capital Management LLC boosted its stake in shares of Hologic by 68.4% during the 1st quarter. AQR Capital Management LLC now owns 1,689,040 shares of the medical equipment provider’s stock worth $59,285,000 after purchasing an additional 686,101 shares during the period. Finally, Royal Bank of Canada boosted its stake in shares of Hologic by 527.6% during the 1st quarter. Royal Bank of Canada now owns 719,977 shares of the medical equipment provider’s stock worth $25,273,000 after purchasing an additional 605,265 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Recommended Story: How can investors invest in the S&P/TSX Index?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.